Selera Medical: One-time, device-based treatment for heart failure
Selera Medical, Inc. · AI Assistant
Selera Medical is developing a one-time, catheter-based device that offloads the lymphatic system to clear fluid overload in chronic heart failure. It's not approved yet.
About Selera Medical: One-time, device-based treatment for heart failure
What Is Selera Medical
Selera Medical, Inc. is a medical device company in the San Francisco Bay Area building a chronic heart failure treatment around fluid, not around the pump. The founders came out of the Stanford Biodesign fellowship, took the company through Y Combinator's W24 batch, and later joined Fogarty Innovation's accelerator. Their product has a name: minimally invasive lymphatic offloading, or MILO.
Fluid is what puts heart failure patients in a hospital bed. Roughly nine in ten symptoms and admissions trace back to fluid collecting somewhere it shouldn't: lungs, legs, belly. Diuretics have been the answer for more than 60 years. They cause side effects, they need monitoring, and for a large share of patients they gradually stop working. Selera puts that share near 30%.
Most heart failure devices work on the pump: assist pumps, resynchronization, pressure monitors. MILO is a fluid overload treatment aimed at the drainage side of the system. When a failing heart backs up, fluid leaks into the interstitial space, the gap between organs and tissue. Lymphatics normally return it to the bloodstream. In heart failure they get swamped, so the fluid sits there. Selera's catheter-based heart failure device is designed to relieve that backup so trapped fluid can move again and the buildup and readmission cycle breaks.
The honest limits are large. The company has run prototypes, bench work and animal studies plus early feasibility work, not a large human trial. Nothing is FDA cleared or approved. There's no price, no billing code, and no way for a patient to ask for it today. Read MILO as a serious idea in development, not a treatment you can book.
Getting Started
This is the pathway the company describes for the procedure. Details will firm up as trials move.
- Raise it with your cardiologist. The useful question is whether your congestion keeps returning on maximum tolerated medication.
- Get evaluated at an interventional center. A heart failure cardiologist or interventionalist reviews your history, imaging, kidney function and current drug regimen.
- Have the catheter procedure. Selera describes a one-time, minimally invasive intervention rather than open surgery.
- Recover under observation. Expect a monitored stay with fluid status, weight and symptoms checked before discharge.
- Follow up. Success is measured in symptoms and hospitalizations over months, not in a daily dose.
Product Information
A quick look at Selera Medical: One-time, device-based treatment for heart failure's pricing, supported platforms, and performance.
Best for
The users, tasks, and scenarios where this tool fits best.
Users
- People with recurring fluid buildup
- Family caregivers
- Cardiologists and interventionalists
- Medtech analysts
Tasks
- Breaking a readmission loop
- Cutting reliance on escalating diuretic doses
- Treating congestion when drugs are maxed out
- Comparing device options for a complex patient
Scenarios
- A patient admitted three times in a year for fluid
- An interventional lab building a heart failure program
- A trial site recruiting refractory congestion cases
- Early scouting for a hospital technology committee
Key features
One Procedure Instead of a Daily Habit
Heart failure fluid management usually depends on what a patient does every morning. MILO is designed as a single intervention with lasting effect, which takes the adherence question off the table. Selera says the benefit persists. No human durability data has been published.
Lymphatic Offloading as the Mechanism
The device works on the lymphatic network, the system that returns fluid from tissue to blood. In heart failure that network is overwhelmed by volume it can't clear. Relieving the bottleneck lets trapped fluid drain instead of pooling in the lungs or legs. That's a different target from devices that assist or reshape the heart.
Aimed at Diuretic-Resistant Patients
Selera frames its patient as someone whose congestion returns despite maximum tolerated medication. That group has almost nothing device-based to fall back on. Going after it means a smaller market and a clearer unmet need, which is often how a startup gets through trials on a limited budget.
Catheter-Based Delivery
The procedure is described as minimally invasive and catheter based, so it belongs in an interventional lab rather than a cardiac surgery suite. That shapes recovery time, cost and which hospitals could offer it. Selera hasn't published the access route or device dimensions.
Built as an Addition to Standard Care
Nothing in the company's material suggests MILO replaces guideline-directed medication. It's positioned next to drugs, as a way to control fluid that drugs no longer control. Patients would stay on their heart failure regimen after the procedure.
Measured on Hospitalizations, Not Just Symptoms
The stated goals are fewer admissions and better quality of life. That's a harder bar than symptom relief, and it happens to be the outcome payers reimburse for. It also means trial results take longer to read.
Pros and cons
Pros
- Goes after the source of most heart failure symptoms: fluid stuck in tissue rather than a weak pump.
- A one-time procedure could remove the daily adherence problem that sinks long-term diuretic therapy.
- Serves patients with the fewest options, the ones whose congestion survives maximum medication.
- Catheter delivery means no open surgery and a lighter recovery than implant procedures.
- Focused on hospitalizations, where most of the cost and most of the harm sit.
Cons
- Not approved for sale anywhere. No FDA clearance, no commercial product in any market.
- No published human efficacy results. The evidence base is preclinical work plus an early feasibility study.
- No price and no reimbursement pathway, so total cost is unknown even in estimates.
- Durability is unproven. Lymphatic channels can remodel, and a single procedure has to hold for years to beat a daily pill.
Frequently asked questions
Selera Medical is a Bay Area device startup developing MILO, a one-time catheter procedure meant to treat fluid overload in chronic heart failure. It's a company and a device program, not a clinic or a consumer product.
Related content
Explore related tools, skills, and articles for Selera Medical: One-time, device-based treatment for heart failure.
Selera Medical: One-time, device-based treatment for heart failure Alternatives
Agibot
Agibot · Productivity · AI Assistant · ChatbotAgibot is a personal AI agent for Mac that keeps running after you close the window, runs routines on a schedule, and works from Telegram or Slack with your own API keys.
Foley
Hanamori Labs, LLC · Voice & Language · Productivity · AI AssistantFoley is a voice to-do list that turns a spoken sentence into a filed task, complete with project, date and time, then helps you plan the day around what is already there.
Ghost Core
Ghost · Productivity · AI AssistantGhost Core is a $3,499 screenless personal AI computer that runs local AI models on its own hardware, builds context from your apps and devices, and acts without waiting for a prompt.